The clinical and public health problem of relapse despite primaquine therapy: case review of repeated relapses of Plasmodium vivax acquired in Papua New Guinea.
BACKGROUND: Primaquine is the only drug available for preventing relapse following a primary attack by Plasmodium vivax malaria. This drug imposes several important problems: daily dosing over two weeks; toxicity in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency; partner blood sch...
Main Authors: | Ingram, R, Crenna-Darusallam, C, Soebianto, S, Noviyanti, R, Baird, J |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2014
|
Similar Items
-
Primaquine as anti-relapse therapy for Plasmodium vivax
by: Baird, J
Published: (1998) -
Therapeutic principles of primaquine against relapse of Plasmodium vivax malaria
by: Baird, J
Published: (2018) -
High-dose primaquine regimens against relapse of Plasmodium vivax malaria.
by: Krudsood, S, et al.
Published: (2008) -
Tafenoquine versus primaquine to prevent relapse of Plasmodium vivax malaria
by: Llanos-Cuentas, A, et al.
Published: (2019) -
Tafenoquine versus primaquine to prevent relapse of plasmodium vivax malaria
by: Watson, J, et al.
Published: (2019)